<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047801</url>
  </required_header>
  <id_info>
    <org_study_id>TLK286.2012</org_study_id>
    <nct_id>NCT00047801</nct_id>
    <nct_alias>NCT00068705</nct_alias>
  </id_info>
  <brief_title>Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telik</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telik</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of TLK286 given&#xD;
      intravenously once every three weeks in combination with docetaxel (Taxotere) in the&#xD;
      treatment of patients with non-small cell lung cancer that is resistant to platinum-based&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>28</enrollment>
  <condition>Carcinoma, Non-small-cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLK286 in combination with docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria include:&#xD;
&#xD;
          -  Histologically confirmed non-small cell bronchogenic carcinoma, including squamous&#xD;
             cell carcinoma, undifferentiated carcinoma, adenocarcinoma, mixed (adenocarcinoma with&#xD;
             squamous cell carcinoma), bronchoalveolar carcinoma, or large cell carcinoma&#xD;
&#xD;
          -  Stage IV or Stage IIIB&#xD;
&#xD;
          -  Progressed during or after first-line therapies with platinum-containing regimens in&#xD;
             the advanced or metastatic treatment regimen&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Good performance status (ECOG 0 to 1)&#xD;
&#xD;
          -  Adequate liver, renal, and bone marrow function&#xD;
&#xD;
        Exclusion criteria include:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Treatment with more than one cytotoxic therapy&#xD;
&#xD;
          -  Prior radiation to the whole pelvis&#xD;
&#xD;
          -  Unstable medical conditions such as uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  Patients with known history of severe hypersensitivity reactions to docetaxel or other&#xD;
             drugs formulated with polysorbate 80&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Institute Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>October 18, 2002</study_first_submitted>
  <study_first_submitted_qc>October 18, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2002</study_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Gail Brown, M.D. Chief Medical Officer</name_title>
    <organization>Telik, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

